I. Figueiredo

435 total citations
8 papers, 228 citations indexed

About

I. Figueiredo is a scholar working on Pulmonary and Respiratory Medicine, Molecular Biology and Oncology. According to data from OpenAlex, I. Figueiredo has authored 8 papers receiving a total of 228 indexed citations (citations by other indexed papers that have themselves been cited), including 5 papers in Pulmonary and Respiratory Medicine, 2 papers in Molecular Biology and 2 papers in Oncology. Recurrent topics in I. Figueiredo's work include Prostate Cancer Treatment and Research (4 papers), Cancer Genomics and Diagnostics (2 papers) and Lung Cancer Treatments and Mutations (2 papers). I. Figueiredo is often cited by papers focused on Prostate Cancer Treatment and Research (4 papers), Cancer Genomics and Diagnostics (2 papers) and Lung Cancer Treatments and Mutations (2 papers). I. Figueiredo collaborates with scholars based in United Kingdom, United States and Netherlands. I. Figueiredo's co-authors include Johann S. de Bono, Susana Miranda, Mateus Crespo, David Lorente, Diletta Bianchini, Howard I. Scher, Gerhardt Attard, Leon W.M.M. Terstappen, Penelope Flohr and Roberta Ferraldeschi and has published in prestigious journals such as British Journal of Cancer, Annals of Oncology and Nutrients.

In The Last Decade

I. Figueiredo

8 papers receiving 227 citations

Peers

I. Figueiredo

PRM

CR

MB

ONCOL

RNMI

Ryan P. McMullin United States

Marthe Løvf Norway

Natalja Eigėlienė Finland

Brad Foulk United States

Nicla De Rosa Italy

Jack Zhu United States

Ruping Zhao China

Nazia Riaz Pakistan

Shuncheng Miao China

Friederike Schlürmann France

Ryan P. McMullin United States

I. Figueiredo

172 ×1.4

PRM

101 ×0.9

CR

147 ×1.6

MB

83 ×0.9

ONCOL

17 ×0.9

RNMI

Citations per year, relative to I. Figueiredo I. Figueiredo (= 1×) peers Ryan P. McMullin

Countries citing papers authored by I. Figueiredo

Since Specialization

Citations

This map shows the geographic impact of I. Figueiredo's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by I. Figueiredo with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites I. Figueiredo more than expected).

Fields of papers citing papers by I. Figueiredo

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by I. Figueiredo. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by I. Figueiredo. The network helps show where I. Figueiredo may publish in the future.

Co-authorship network of co-authors of I. Figueiredo

This figure shows the co-authorship network connecting the top 25 collaborators of I. Figueiredo. A scholar is included among the top collaborators of I. Figueiredo based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with I. Figueiredo. I. Figueiredo is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

8 of 8 papers shown

1.

Corrêa, Diogo Goulart, et al.. (2024). Holoprosencephaly spectrum: an up-to-date overview of classification, genetics and neuroimaging. Japanese Journal of Radiology. 43(1). 13–31. 1 indexed citations

2.

Figueiredo, I., et al.. (2024). Nutritional Genomics: Implications for Age-Related Macular Degeneration. Nutrients. 16(23). 4124–4124. 2 indexed citations

3.

Tzankov, Alexandar, Ruth Plummer, Igor Vivanco, et al.. (2020). 382P The potential utility of end-binding protein 1 (EB1) as response-predictive biomarker for lisavanbulin: Final results from a phase I study of lisavanbulin (BAL101553) in adult patients with recurrent glioblastoma (GBM). Annals of Oncology. 31. S404–S404. 2 indexed citations

4.

Lorente, David, David Olmos, Joaquı́n Mateo, et al.. (2018). Circulating tumour cell increase as a biomarker of disease progression in metastatic castration-resistant prostate cancer patients with low baseline CTC counts. Annals of Oncology. 29(7). 1554–1560. 72 indexed citations

5.

Rescigno, Pasquale, Mattia Rediti, David Dolling, et al.. (2018). PI3K/AKT pathway deleterious mutations in lethal prostate cancer. Annals of Oncology. 29. viii293–viii293. 3 indexed citations

6.

Crespo, Mateus, Guus van Dalum, Roberta Ferraldeschi, et al.. (2015). Androgen receptor expression in circulating tumour cells from castration-resistant prostate cancer patients treated with novel endocrine agents. British Journal of Cancer. 112(7). 1166–1174. 53 indexed citations

7.

Ong, Michael, Suzanne Carreira, Jane Goodall, et al.. (2014). Validation and utilisation of high-coverage next-generation sequencing to deliver the pharmacological audit trail. British Journal of Cancer. 111(5). 828–836. 23 indexed citations

8.

Bianchini, Diletta, Aurelius Omlin, Carmel Pezaro, et al.. (2013). First-in-human Phase I study of EZN-4176, a locked nucleic acid antisense oligonucleotide to exon 4 of the androgen receptor mRNA in patients with castration-resistant prostate cancer. British Journal of Cancer. 109(10). 2579–2586. 72 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact